AUTHORS
Lauren Turecki, MD, Pedro Luiz Lage Bodour Danielian, MD, MPH2, Sean Bowden, MD3, Mara Epstein, ScD4, Sakiko A Suzuki, MD5, Andrew Gillis-Smith, MD6, Shyam A Patel, MD, PhD7, Laurie K Pearson, MD8, Muthalagu Ramanathan, MD9, Jan Cerny, MD, PhD10, Poorva Bindal, MD11
AFFILIATIONS
1 UMass Chan Medical School, Worcester, Massachusetts, United States
2 UConn Health, Farmington, Connecticut, United States
3 UMass Chan Medical School, Worcester, Massachusetts, United States
4 Boston University School of Medicine, Boston, Massachusetts, United States
5 UMass Chan Medical School, Worcester, Massachusetts, United States
6 UMass Chan Medical School, Worcester, Massachusetts, United States
7 UMass Chan Medical School, Worcester, Massachusetts, United States
8 UMass Chan Medical School, Worcester, Massachusetts, United States
9 UMass Chan Medical School, Worcester, Massachusetts, United States
10 UMass Chan Medical School, Worcester, Massachusetts, United States
11 UMass Chan Medical School, Worcester, Massachusetts, United States
ABSTRACT
Background:? Transformed follicular lymphoma (tFL) is characterized by aggressive disease biology and inferior outcomes after relapse. Current therapies are based on de novo dDLBCL guidelines, however tFL has inferior survival to DLBCL. CD19-directed chimeric antigen receptor T-cell (CAR T) therapy has shown substantial activity in relapsed/refractory (R/R) tFL; however, treatment failure and early death remain clinically important, particularly among patients with refractory disease or impaired functional status. Early mortality may reflect progressive lymphoma, treatment-related toxicity, infection, or organ failure, but its incidence, causes, and predictors after CAR T therapy in tFL are not well defined. We performed a secondary analysis of a publicly available Center for International Blood and Marrow Transplant Research (CIBMTR) dataset to quantify early mortality, characterize causes of death, and identify factors associated with relapse/progression-related mortality after commercial CAR T therapy in patients with R/R tFL.?
Methods:? We included patients with R/R tFL treated with commercially available CAR T-cell therapy in the publicly available CIBMTR dataset. The analysis leveraged registry-reported patient, disease, treatment, toxicity, and hematopoietic recovery variables. Early mortality was defined as death within 180 days of CAR T-cell infusion. Outcomes included mortality at 30, 100, and 180 days and the primary cause of death within 180 days. Causes were categorized as relapse/progression, infection, organ failure, malignancy, treatment-related toxicity including CRS, ICANS and tumor lysis syndrome (TLS), or other/unspecified. Overall survival was estimated using Kaplan-Meier methods with administrative censoring at day 180. A multivariable cause-specific Cox proportional hazards model incorporating time-varying covariates evaluated associations with death from relapse/progression. Candidate variables included age, Karnofsky Performance Status (KPS), disease status before infusion, receipt of bridging therapy, ICANS, CRS, and neutrophil recovery. KPS was available only as <90 versus 90-100. A day-30 landmark analysis was performed among patients alive and under observation at day 30 to mitigate immortal-time bias related to post-infusion covariates.
Results:? Among 923 patients with R/R tFL treated with commercial CD19-directed CAR T-cell therapy, mortality was 2.60% at 30 days, 11.59% at 100 days, and 19.93% at 180 days. Relapse/progression accounted for 70.65% of deaths within 180 days, followed by infection (13.0%), organ failure (9.2%), and treatment-related toxicity (2.7%). In the multivariable cause-specific model, lower KPS (<90 versus 90-100) was associated with a 50% higher risk of death from relapse/progression (hazard ratio [HR], 1.50; 95% CI, 1.13–1.98). Resistant disease before infusion (HR, 2.28; 95% CI, 1.36–3.81) and receipt of bridging therapy (HR, 2.15; 95% CI, 1.44–3.19) were each associated with more than a twofold increased risk. Age, CRS, and ICANS were not independently associated with relapse/progression-related mortality. Findings remained consistent in the day-30 landmark analysis with lower KPS (HR, 1.44; 95% CI, 1.08–1.92), resistant disease (HR, 2.12; 95% CI, 1.26–3.57), and bridging therapy (HR, 2.16; 95% CI, 1.44–3.26) remaining significantly associated with relapse/progression-related mortality, whereas age, CRS, and ICANS did not.?
Conclusion:? Early mortality remains substantial after CAR T-cell therapy for R/R tFL, affecting approximately 20% of patients by day 180. Relapse/progression, rather than immune-mediated toxicity, was the dominant cause of early death. Lower functional status, resistant disease at infusion, and the need for bridging therapy identified patients at greatest risk of relapse/progression-related mortality. Bridging therapy likely serves as a marker of aggressive disease biology or an urgent need for disease control rather than an inherently harmful intervention. These findings support earlier referral for CAR T evaluation, strategies to improve disease control before infusion, and intensified post-infusion surveillance for high-risk patients. Prospective studies are needed to validate these risk factors and determine whether interventions that reduce disease burden before infusion can improve early survival.?
Disclosure: Data used from the PAD from CIBMTR was not reviewed by CIBMTR and findings here do not reflect their own conclusions.
DISCLOSURES
Lauren Turecki, MD: No relevant conflicts of interest to declare.